📰 Hartmutj Ehrlich News
Page 2 - Hartmutj Ehrlich News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hartmutj Ehrlich. Real-time updates on events, politics, business and more.
April 19, 2023
EQS-News: ABIVAX / Key word(s): Annual ResultsAbivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax reports 2022 financial results and operations update Obefazimod global pivotal phase 3 program (ABTECT...
April 18, 2023
Michael Ferguson has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically
April 18, 2023
EQS-News: ABIVAX / Key word: Personnel Abivax appoints Michael Ferguson as Chief Commerical Officer 18.04.2023 / 18:00 CET/CEST The issuer is solely responsible for the content... | April 18, 2023
April 17, 2023
Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase ...
April 17, 2023
The analysis demonstrates clinical remission in 52.5% (n=114) of 217 moderate to severe ulcerative colitis (UC) patients (intent-to-treat population, ITT) after two years (96 weeks) of once-daily oral
April 17, 2023
EQS-News: ABIVAX / Key word(s): Study results Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance tri...
April 17, 2023
EQS-News: ABIVAX / Key word: Study results Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis 17.04.2023 / 18:00... | April 17, 2023
April 6, 2023
Our lead drug candidate, obefazimod, has generated promising results in Phase IIa and Phase IIb clinical trials for the treatment of ulcerative colitis, a chronic inflammatory bowel disease, and in a Phase IIa clinical trial in rheumatoid arthritis.
April 5, 2023
EQS-News: ABIVAX / Key word: Personnel Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair 05.04.2023 / 19:30 CET/CEST The issuer is solely... | April 5, 2023
April 5, 2023
Abivax Appoints Marc de Garidel as Chief Executive Officer and Interim ...